How to protect against the most pressing threat to healthcare clouds today

Healthcare IT News | February 14, 2020

The most pressing threat against clouds in healthcare today is the insufficient protection of sensitive data both where physical and logical safeguards are implemented, especially when new cloud technology is introduced to existing systems. That is the conclusion of Howard Young, director, solutions architecture, at Zadara Storage, a hybrid cloud storage vendor that delivers enterprise storage as a fully managed service. Often, protective controls are overlooked or missed in megalithic hyperscale clouds simply due to the sheer nature of the platform, whereas smaller, agile cloud providers may provide a better fit in the healthcare industry,” he contended. “Since the cloud is a third-party environment, routine security checks – such as PEN testing – are necessary to ensure environment configurations remain consistent and intact.

Spotlight

This case study shows how one hospital was able to overcome negative perceptions and improve adoption by introducing evidence-based plans of care. A cross-departmental team developed a holistic approach using electronic collaboration tools.


Other News
HEALTH TECHNOLOGY

PulsePoint Releases Next Generation Health Media Platform With Advanced Automation And AI

PulsePoint | July 06, 2021

PulsePoint, a technology company revolutionizing health decision-making in real-time, today announced the next generation launch of its digital media buying platform, Life by PulsePoint™. Its enhanced AI and automation simplifies and supercharges the media planning, activation, and optimization processes. Designed for the self-serve programmatic trader, these updates promote efficiencies and surface predictive and in-flight campaign analytics for quick strategic decisioning to yield higher media return on investment. Built upon PulsePoint's extensive data foundation, Genome™, that proactively uses microdata to capture attention when intent is signaled, Life is the leading healthcare end-to-end programmatic platform. Life's automated machine learning and AI allows marketers to quickly create highly-customized segments that classify populations in real-time, and deliver sequential messaging to drive customer actions in the moment and across the health journey. This next generation of the Life platform includes: • Advanced media planning innovations: Life offers an AI-powered forecasting tool used to run simulations to generate predictive performance metrics and intelligent audience insights. This makes it easier for marketers to preview budgets and ideate and adjust tactics to obtain their desired campaign outcomes, all before a single dollar is spent. Each forecast is powered by detailed supply and channel insights, like expected delivery, and campaign performance can be viewed by a variety of dimensions, including creative types, domains/apps, condition categories, healthcare professional specialties, geographies, among others. • Better campaign management with advanced dashboard: An automated and real-time view of line item performance and pacing gives traders a deeper, more granular look into their campaigns, making it easier for them to optimize their spend based on flight delivery and anticipate new incremental opportunities. The dashboard not only surfaces key numbers, but it also includes dynamic performance charts to uncover real-time campaign insights. • Turnkey PMP (private marketplaces) deal builder: Enhanced with turnkey end-to-end functionality, self-serve traders can now enable the deals that they negotiated directly with publishers and/or SSPs through Life's UI, decreasing the time it takes to launch PMPs. "Life was built for the healthcare marketer to simplify and optimize marketing campaigns," said Andrew Stark, CRO of PulsePoint. "Our newest capabilities increase efficiencies through advanced forecasting and real-time performance optimization, enabling more control and enhanced campaign management." Life by PulsePoint provides access to over 110 billion daily impressions across more than 2 million health pages, reaching 1.8M+ opted-in, verified healthcare professionals and over 90% of the online U.S. population. This release is just another step in PulsePoint's journey to deliver personalized messaging at each stage of the health journey using predictive insights built on real-time data. The company was recently acquired by Internet Brands, a KKR portfolio company and owner of WebMD Health Corp. PulsePoint's teams will continue to operate as their own division from their existing hubs in New York, San Francisco, and London. About PulsePoint PulsePoint is a leading technology company that uses real-world data in real-time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint targets healthcare professionals and patients with an unprecedented level of accuracy—delivering unparalleled results to the clients we serve.

Read More

MEDICAL DEVICES

CeloNova Announces New Strategic Direction Focused on Creating Partnership

CeloNova BioSciences, Inc. | April 08, 2022

CeloNova BioSciences, Inc. developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company's nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date. "We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects," stated Carl St. Bernard, President and Chief Executive Officer of CeloNova. "This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies." "I fully support CeloNova's new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F. When my students and I set out to study the hemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realized its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices." Professor Dr. Michael Grunze, Former Chair and Professor (emeritus) at the Institute of Applied Physical Chemistry of the Ruprecht-Karls-University in Heidelberg and co-inventor of Polyzene-F CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the U.S. and the EU. The company's PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated Coronary Stent, was developed to safely and effectively treat patients who may benefit from 1-month of dual antiplatelet therapy. CeloNova's new business direction builds upon the successful application of PzF in interventional oncology and cardiology and expands its opportunities through the development of new surface coating technologies to address important unmet clinical needs. "In my pre-clinical research at CVPath since 2012, CeloNova's proprietary Polyzene-F coating has consistently demonstrated a unique advantage of allowing an implant to heal quickly and in a functional way, without the need for antiproliferative drug elution," stated Aloke Finn, MD, Medical Director and Chief Scientific Officer at CVPath and Associate Professor of Medicine at the University of Maryland. "I believe Polyzene-F will continue to play an important role in delivering safety and efficacy in clinical practice." Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.1* About CeloNova BioSciences, Inc. CeloNova BioSciences, Inc. is a global medical device company that develops, manufactures and markets novel surfaced coated technologies, including its proprietary Polyzene™-F nanocoating. The next generation nanocoating is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.

Read More

MEDICAL DEVICES

Lark Health Builds AI-Driven Heart Health Program

Lark Health | March 17, 2022

Lark Health today announced the development of a novel AI-driven program for the prevention and management of atherosclerotic cardiovascular disease and coronary artery disease in collaboration with Roche Diagnostics. The program, named Lark Heart Health, is an AI-driven virtual care solution that provides personalized health coaching anytime, anywhere. The new Heart Health program is planned to launch later this year. Cardiovascular disease is the leading cause of death globally, and nearly half of all adults in the U.S. have some form of CVD. It's also one of the most expensive chronic conditions, with heart disease and stroke costing the U.S. healthcare system roughly $214 billion annually. Yet, provider shortages and siloed care teams leave patients with limited care options, gaps in care, and insufficient education and empowerment to self-manage their heart health. Additionally, high treatment costs and resource constraints often limit care to those with the highest acuity conditions. Built using a Cognitive Behavioral Therapy framework and designed in accordance with guidelines from the American Heart Association (AHA), Lark Heart Health will provide a cost-effective, scalable solution for continuous, person-centric remote heart health coaching intended to help users improve their healthy lifestyle behaviors, reduce stress levels, and ultimately decrease risk factors for heart disease. Through an evidence-based educational curriculum and real-time personalized coaching, Lark will provide users with the tools they need to make meaningful lifestyle changes that can help them better prevent and manage ASCVD and CAD. Earlier this year, Lark announced it had joined the AHA's Network at American Heart Association Center of Health Technology & Innovation, which is focused on building and fostering health technology relationships to develop innovative and scalable solutions. "Lark Heart Health will help those at high risk prevent and actively manage cardiovascular disease through personalized digital coaching. By leveraging our AI technology, we can deliver meaningful and engaging care at an unprecedented scale, and this collaboration with Roche Diagnostics will support the expansion of our proven tech platform into one of the costliest chronic disease markets." Julia Hu, co-founder and CEO of Lark About Lark Health Lark is a healthcare technology company aimed at delivering infinitely scalable, virtual chronic and preventative healthcare through conversational AI. To date, Lark has provided nearly 2 million people with unlimited, 24/7 personalized care delivered through an easy-to-use, text message-like interface that integrates remote patient monitoring tools and is built on a cognitive behavioral therapy framework. Lark's platform seamlessly integrates with health plans' and employers' existing healthcare infrastructure to help them scale their chronic disease prevention and management programs, boost engagement, and improve health outcomes. Lark currently works with many of the largest health plans and across four programs: Prevention, Diabetes Prevention, Diabetes Care, and Hypertension Care. Lark's Diabetes Prevention Program, which is the fastest growing and lowest cost DPP, has received the highest level of clinical recognition—Full Recognition—from the Centers for Disease Control and Prevention. The company has received numerous accolades, including having been named as one of CB Insights Digital Health 150 (2019), a finalist for the UCSF Digital Health Awards one of Fast Company's Most Innovative Companies and one of Fierce Healthcare's Fierce 15.

Read More

HEALTH TECHNOLOGY

Murata Vios Announces Integration with PointClickCare’s EHR Platform

Murata Vios, Inc | June 24, 2022

Murata Vios, Inc., developer of the Vios Monitoring System, is proud to announce the launch of its integration with PointClickCare, the leading cloud‐based software vendor for the senior care market. The integration will allow healthcare facilities to seamlessly integrate vital signs data into residents’ electronic health records for clinical review, helping to eliminate data entry time lags, transcription errors, and improve clinician efficiency. “Real‐time understanding of a resident’s vital signs can help prevent hospital readmissions because care teams can more quickly identify and treat the early signs of clinical deterioration. With the Vios Monitoring System and its Remote Monitoring Services, PointClickCare customers have a better way to capture this data and respond to changes in a resident’s condition. It can also free up clinical time that was previously spent on manually spot‐checking and recording vital signs every few hours.” Amit Patel, CEO of Murata Vios The Vios Monitoring System is a wireless, FDA‐cleared patient monitoring platform designed to improve resident safety and outcomes. The system delivers insights and value to post‐acute care providers by Continuously monitoring vital signs. The Vios Monitoring System measures high‐fidelity 7‐lead ECG, heart rate, oxygen levels, pulse rate, respiratory rate, and posture data. Improving 24/7/365 oversight of changes in resident conditions. With Vios Remote Monitoring Services, a team of cardiac‐trained technicians can alert the on‐site care team to any changes in a resident’s condition, enabling them to quickly respond to resident deterioration that could lead to readmission. Identifying risk of pressure injuries. The Vios Chest Sensor has a built‐in 3‐axis accelerometer that detects and displays the resident’s posture in real‐time. When turn orders are added, the system can determine when a patient is at‐risk of developing a pressure injury so the on‐site care team can address the issue. Additional information regarding the integration can be found on the PointClickCare Marketplace – an online platform that enables customers to easily evaluate authorized third-party technology partners. Partners listed on the PointClickCare Marketplace offer integrated apps and/or services that are designed to be quickly deployed and work seamlessly with providers’ existing workflows. “The PointClickCare Marketplace offers the widest range of integrated solutions available to the market,” says Chris Beekman, Marketplace Director, PointClickCare. “Our partnership with Murata Vios is further testament to our continually growing partner network and ecosystem, and the wealth of possibilities it provides our customers to extend their technology capabilities.” About Murata Vios, Inc. Murata Vios, Inc., a subsidiary of Murata Manufacturing Co., Ltd., developed the Vios Monitoring System (VMS) to improve patient outcomes and reduce costs across the care continuum. Healthcare facilities can use the wireless, FDA‐cleared vital signs monitoring solution on existing IT infrastructure and instantly deploy the VMS to meet the acuity needs of patients across various care settings. Vios Remote Monitoring Services support healthcare teams with real‐time patient event analysis and notifications, helping to maximize patient safety while minimizing the burden on stretched clinical staff. About PointClickCare PointClickCare is a leading healthcare technology platform enabling meaningful collaboration and access to real‐time insights at any stage of a patient’s healthcare journey. PointClickCare’s single platform spans the care continuum, fostering proactive, holistic decision‐making and improved outcomes for all. Over 22,000 long‐term post‐acute care providers, and 1,600 hospitals use PointClickCare today, enabling care collaboration and value‐based care delivery for millions of lives across North America.

Read More

Spotlight

This case study shows how one hospital was able to overcome negative perceptions and improve adoption by introducing evidence-based plans of care. A cross-departmental team developed a holistic approach using electronic collaboration tools.

Resources